What was the overall valuation of the US osteoarthritis market in 2024?

The overall market valuation was $895.6 Million in 2024. Read More

What is the projected market valuation for the US osteoarthritis market by 2035?

The projected valuation for 2035 is $2339.22 Million. Read More

What is the expected CAGR for the US osteoarthritis market during the forecast period 2025 - 2035?

The expected CAGR for the market during this period is 9.12%. Read More

Which companies are considered key players in the US osteoarthritis market?

Key players include Johnson & Johnson, Pfizer Inc., Boehringer Ingelheim, Novartis AG, AbbVie Inc., Amgen Inc., Sanofi, GlaxoSmithKline, and Eli Lilly and Company. Read More

What are the market segments for the US osteoarthritis market?

The market segments include Type, Diagnosis, Treatment, and End User. Read More

What was the valuation for hip osteoarthritis in 2024?

The valuation for hip osteoarthritis was $358.56 Million in 2024. Read More

What is the projected valuation for spinal osteoarthritis by 2035?

The projected valuation for spinal osteoarthritis by 2035 is $1389.61 Million. Read More

What are the projected valuations for imaging and joint fluid analysis in 2035?

The projected valuations are $1000.0 Million for imaging and $1339.22 Million for joint fluid analysis. Read More

What was the valuation for medication treatment in 2024?

The valuation for medication treatment was $350.0 Million in 2024. Read More

What is the projected valuation for hospitals as an end user by 2035?

The projected valuation for hospitals as an end user by 2035 is $1395.22 Million. Read More

US Osteoarthritis Market

ID: MRFR/Pharma/16454-HCR

100 Pages

Nidhi Mandole

Last Updated: April 06, 2026

United States Osteoarthritis Market Research Report: Size, Share, Trend Analysis By Types (Hip Osteoarthritis, Spinal Osteoarthritis) By t End User (Hospitals, Medical Institutes) By Diagnosis (Imaging, Joint Fluid Analysis) By Treatment (Medication, Surgery, Therapy) - Growth Outlook & Industry Forecast 2025 To 2035

US Osteoarthritis Market

Market Size

Forecast Period2025 - 2035

CAGR (2025 - 2035)9.12%

2024 Market Size$ 895.6 Million

2025 Market Size$ 977.28 Million

2035 Market Size$ 2,339.22 Million

Key Players

Johnson & Johnson

Pfizer Inc.

Boehringer Ingelheim

Novartis AG

AbbVie Inc.

Amgen Inc.

Trends

Rise in Non-Pharmacological Treatments
Technological Innovations in Treatment
Focus on Patient-Centric Care

Opportunities

Rising Healthcare Expenditure
Increased Awareness and Education
Growing Demand for Personalized Medicine

Summary Table of Contents Segmentation Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Construction, BY Type (USD Million)
  1. 4.1.1 Hip Osteoarthritis
  2. 4.1.2 Spinal Osteoarthritis
2. 4.2 Construction, BY Diagnosis (USD Million)
  1. 4.2.1 Imaging
  2. 4.2.2 Joint Fluid Analysis
3. 4.3 Construction, BY Treatment (USD Million)
  1. 4.3.1 Medication
  2. 4.3.2 Surgery
  3. 4.3.3 Therapy
4. 4.4 Construction, BY End User (USD Million)
  1. 4.4.1 Hospitals
  2. 4.4.2 Medical Institutes
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Construction
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Construction
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Johnson & Johnson (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Pfizer Inc. (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Boehringer Ingelheim (DE)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Novartis AG (CH)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 AbbVie Inc. (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Amgen Inc. (US)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Sanofi (FR)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 GlaxoSmithKline (GB)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Eli Lilly and Company (US)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 US MARKET ANALYSIS BY TYPE
3. 6.3 US MARKET ANALYSIS BY DIAGNOSIS
4. 6.4 US MARKET ANALYSIS BY TREATMENT
5. 6.5 US MARKET ANALYSIS BY END USER
6. 6.6 KEY BUYING CRITERIA OF CONSTRUCTION
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF CONSTRUCTION
9. 6.9 DRIVERS IMPACT ANALYSIS: CONSTRUCTION
10. 6.10 RESTRAINTS IMPACT ANALYSIS: CONSTRUCTION
11. 6.11 SUPPLY / VALUE CHAIN: CONSTRUCTION
12. 6.12 CONSTRUCTION, BY TYPE, 2024 (% SHARE)
13. 6.13 CONSTRUCTION, BY TYPE, 2024 TO 2035 (USD Million)
14. 6.14 CONSTRUCTION, BY DIAGNOSIS, 2024 (% SHARE)
15. 6.15 CONSTRUCTION, BY DIAGNOSIS, 2024 TO 2035 (USD Million)
16. 6.16 CONSTRUCTION, BY TREATMENT, 2024 (% SHARE)
17. 6.17 CONSTRUCTION, BY TREATMENT, 2024 TO 2035 (USD Million)
18. 6.18 CONSTRUCTION, BY END USER, 2024 (% SHARE)
19. 6.19 CONSTRUCTION, BY END USER, 2024 TO 2035 (USD Million)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY TYPE, 2025-2035 (USD Million)
  2. 7.2.2 BY DIAGNOSIS, 2025-2035 (USD Million)
  3. 7.2.3 BY TREATMENT, 2025-2035 (USD Million)
  4. 7.2.4 BY END USER, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

US Osteoarthritis Market Segmentation

US Osteoarthritis Market By Type (USD Million, 2025-2035)

Hip Osteoarthritis
Spinal Osteoarthritis

US Osteoarthritis Market By Diagnosis (USD Million, 2025-2035)

Imaging
Joint Fluid Analysis

US Osteoarthritis Market By Treatment (USD Million, 2025-2035)

Medication
Surgery
Therapy

US Osteoarthritis Market By End User (USD Million, 2025-2035)

Hospitals
Medical Institutes

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”